Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Invitrogen Awarded $970K Contract by U.S. Department of Defense

Published: Friday, January 13, 2006
Last Updated: Friday, January 13, 2006
Bookmark and Share
Invitrogen has been awarded to produce and validate protein microarrays to biothreat agents.

Invitrogen Corporation has announced that its subsidiary, Invitrogen Federal Systems, was awarded a $970K Technical Assistance Agreement by the U.S. Department of Defense to produce and validate protein microarrays to biothreat agents.

This work will be conducted under the direction of Dr. James Meegan, Senior Director of Research & Development at Invitrogen, and is designed to support the U.S. Army Medical Research and Materiel Command's (USAMRMC) mission to provide solutions to medical problems of importance to the American war fighter at home and abroad.

Invitrogen's ProtoArray™ protein microarrays consist of complete sets of pure, functional proteins from specific organisms spotted onto glass slides in a high density configuration.

Developed in 2001 as a means to significantly enhance the detection and analysis of biomolecular interactions, Invitrogen has commercialized this technology using protein sets derived from both the yeast and human genomes.

"These products have proven to be exceptionally useful in the assessment of protein:protein interactions and to facilitate autoimmune disease research," said Dr. Barry Schweitzer, Director, Protein Array Center, Invitrogen Corporation.

"Applications for this type of proteomic study continue to grow, creating the need for continuous advancement in research technologies. The evolution of the ProtoArray™ has paralleled this need and we will continue to advance this content moving forward."

"The protein arrays to be developed under this agreement will help to expedite the development of diagnostics, vaccines, and therapeutics and will help assess the level of protection and vulnerability of individuals and populations to threats by these specific biological agents," explained Claude Benchimol, PhD, Senior Vice President, Global Research & Development, Invitrogen Corporation.

"They will also enable the Department of Defense research community to explore the mechanism by which these microorganisms cause disease and the means by which man develops protective responses in new and unprecedented detail."

"The advantages this tool will provide the military community are directly translatable to protection of the civilian community against a bioterrorist attack."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Invitrogen Develops new Technology to Promote Safer Stem Cell Therapies
Dynabeads’ solution separates undifferentiated stem cells from differentiated cells to support translational research.
Thursday, May 14, 2009
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Experimental Therapy For Brain Cancer Could Prevent Drug Resistance
Information from penny-sized microfluidic chips allowed researchers to anticipate resistance to cancer treatment.
3D Printing of Lego Fluidics
Study shows how 3D printing can open up microfluidic technology to a wider audience.
New Method to Preserve Device to Monitor HIV Treatment
Inspired by pregnancy tests, scientists have developed a method to store microfluidic devices for months without refrigeration, giving developing countries an inexpensive and reliable way to treat patients.
Migration Creates Cancer Cell Vulnerabilities
Scientists found that migration can damage cancer cells’ nuclei and DNA, requiring repairs for their survival. The results may open new avenues for targeting metastatic cancer.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!